Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Gufic Biosciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1985 on BSE, Oct 2004 on NSE
Last close ₹423.75up ₹3.30 (0.78%)BSE ₹423.70
Share price at the NSE close on 28 Oct 2026. Previous close ₹420.45.
28 Oct: open ₹420.95, high ₹430.70, low ₹414.15
52-week range of traded prices to 28 Oct 2026
₹268.00Low, 9 Mar 2026₹467.80High, 7 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,249 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,56,95560.7% delivered
Gufic Biosciences disputes and clarifications
21 filed, newest first.
Sep 2026
Apr 2025
Mar 2025
Nov 2024
4 Nov · Legal
The exchange asked on 4 Nov 2024
Jun 2024
11 Jun · Legal
The exchange asked on 10 Jun 2024
Nov 2023
16 Nov · Legal
The exchange asked on 16 Nov 2023
Jun 2023
17 Jun · Legal
The exchange asked on 16 Jun 2023
Dec 2022
12 Dec · Legal
Exchange has sought clarification from Gufic Biosciences Limited with respect to Financial Results dated 11-Nov-2022 for the period Sep, 2022:On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:1. Consolidated: Financial Results - Not submittedThe response of the company is awaited.
May 2021
13 May · Legal
The exchange asked on 12 May 2021
Mar 2021
1 Mar · Legal
Exchange has sought clarification from Gufic Biosciences Limited for the quarter ended 31-Dec-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
Apr 2020
10 Apr · Legal
The exchange asked on 9 Apr 2020
Jun 2019
4 Jun · Legal
Exchange has sought clarification from Gufic Biosciences Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Feb 2019
Jun 2018
May 2018
30 May · Legal
Exchange has sought clarification from Gufic Biosciences Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Dec 2017
18 Dec · Legal
Exchange has sought clarification from Gufic Biosciences Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted within 30 minutes from end of board meeting. -2. Segment details not submitted The response of the Company is awaited.
Oct 2017
25 Oct · Legal
The exchange asked on 24 Oct 2017
Jul 2014
8 Jul · Legal
Price movement : Significant price movement has been observed in Gufic Biosciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Gufic Biosciences Limited has vide its letter inter-alia stated,"We would like to take your note that company has got recognition for In-House R&D unit(s) located at N.H. No. 8, Near Grid, Kablipore, Navsari, Gujarat from May 05th, 2014 to March 31st, 2017 from the Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, Government of India".